EUVIMEDEUVIMED entdecken
Open Access

Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence

Jingli Gao iD, Yuhao Li, Yijun Zhang, Xin Zhan iD, Xue Tian, Junjuan Li iD, Ru Wang iD, Yan He iD, Anxin Wang iD, Shouling Wu iD

Journal of the American Heart Association · 05.03.2024 · 13 (5)

DOI: 10.1161/jaha.123.032604 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, erschienen am 05.03.2024. Verfasst von Jingli Gao und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit Kailuan General Hospital Tangshan China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background The association of the severity of hepatic steatosis in metabolic dysfunction–associated fatty liver disease (MAFLD)/metabolic dysfunction–associated steatotic liver disease (MASLD) and the remission of MAFLD/MASLD with CKD occurrence is unclear. Methods and Results The study enrolled 79 540 participants from the Kailuan cohort. Hepatic steatosis was diagnosed by ultrasound. MAFLD/MASLD was defined as hepatic steatosis combined with metabolic dysfunction and MASLD further excluded alcohol or other causes of liver disease. Chronic kidney disease (CKD) was defined as estimated glomerular filtration rate

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseRenal Insufficiency, ChronicHumansEthanolCausalityProteinuria

Stichwörter der Autor:innen

chronic kidney disease (CKD)metabolic dysfunction–associated fatty liver disease (MAFLD)metabolic dysfunction–associated steatotic liver disease (MASLD)severity of hepatic steatosis

Substanzen

Ethanol

Autor:innen und Institutionen

  • Department of Intensive Care Unit Kailuan General Hospital Tangshan China.
  • Department of Epidemiology and Health Statistics, School of Public Health Capital Medical University Beijing China.
  • Beijing Municipal Key Laboratory of Clinical Epidemiology Beijing China.
  • Department of Neurology Beijing Tiantan Hospital Capital Medical University Beijing China.
  • China National Clinical Research Center for Neurological Diseases Beijing Tiantan Hospital Capital Medical University Beijing China.
  • Department of Clinical Epidemiology and Clinical Trial Capital Medical University Beijing China.

ORCID-Profile: Jingli Gao, Xin Zhan, Junjuan Li, Ru Wang, Yan He, Anxin Wang, Shouling Wu

Zitieren

APA

Gao, J., Li, Y., Zhang, Y., Zhan, X., Tian, X., Li, J., Wang, R., He, Y., Wang, A., & Wu, S. (2024). Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence. Journal of the American Heart Association, 13(5). https://doi.org/10.1161/jaha.123.032604

Vancouver

Gao J, Li Y, Zhang Y, Zhan X, Tian X, Li J, et al. Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence. Journal of the American Heart Association. 2024;13(5). doi:10.1161/jaha.123.032604

BibTeX
@article{Gao2024,
  author = {Gao, Jingli and Li, Yuhao and Zhang, Yijun and Zhan, Xin and Tian, Xue and Li, Junjuan and Wang, Ru and He, Yan and Wang, Anxin and Wu, Shouling},
  title = {Severity and Remission of Metabolic Dysfunction–Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence},
  journal = {Journal of the American Heart Association},
  year = {2024},
  volume = {13},
  number = {5},
  doi = {10.1161/jaha.123.032604}
}
Kostenlos starten →